Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Clemons

Showing results (181-190 of 267) with videos related to

Pageof 27
Sort By:
Systematic Reviews|July 8, 2023
Can routinely collected administrative data effectively be used to evaluate and validate endpoints used in breast cancer clinical trials? Protocol for a scoping review of the literatureHely Shah, Dianna Wolfe, Mark Clemons, et al.
Journal of Bone Oncology|February 25, 2016
Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient surveyBrian Hutton, Patricia Morretto, Urban Emmenegger, et al.
Breast (Edinburgh, Scotland)|March 15, 2023
Regularly scheduled physical examinations and the detection of breast cancer recurrencesAna-Alicia Beltran-Bless, Bader Alshamsan, Mashari Jemaan Alzahrani, et al.
Cancer Medicine|March 31, 2018
The importance of greater speed in drug development for advanced malignanciesDavid J Stewart, Andrew A Stewart, Paul Wheatley-Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancerEitan Amir, Naomi Miller, William Geddie, et al.
Breast Cancer Research and Treatment|May 13, 2019
De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysisArif Ali Awan, Brian Hutton, John Hilton, et al.
Breast Cancer Research : BCR|September 26, 2013
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerRebecca A Dent, Geoffrey J Lindeman, Mark Clemons, et al.
Clinical Breast Cancer|September 26, 2019
Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic InformationSusan J Robertson, Greg R Pond, John Hilton, et al.
Breast Cancer Research and Treatment|June 25, 2009
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patientsOrit Freedman, Eitan Amir, George Dranitsaris, et al.
The Oncologist|August 5, 2010
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortiumSara K Taylor, Stephen Chia, Susan Dent, et al.
Pageof 27

Showing results (181-190 of 267) with videos related to

Sort By:
Pageof 27
Systematic Reviews|July 8, 2023
Can routinely collected administrative data effectively be used to evaluate and validate endpoints used in breast cancer clinical trials? Protocol for a scoping review of the literatureHely Shah, Dianna Wolfe, Mark Clemons, et al.
Journal of Bone Oncology|February 25, 2016
Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient surveyBrian Hutton, Patricia Morretto, Urban Emmenegger, et al.
Breast (Edinburgh, Scotland)|March 15, 2023
Regularly scheduled physical examinations and the detection of breast cancer recurrencesAna-Alicia Beltran-Bless, Bader Alshamsan, Mashari Jemaan Alzahrani, et al.
Cancer Medicine|March 31, 2018
The importance of greater speed in drug development for advanced malignanciesDavid J Stewart, Andrew A Stewart, Paul Wheatley-Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancerEitan Amir, Naomi Miller, William Geddie, et al.
Breast Cancer Research and Treatment|May 13, 2019
De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysisArif Ali Awan, Brian Hutton, John Hilton, et al.
Breast Cancer Research : BCR|September 26, 2013
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerRebecca A Dent, Geoffrey J Lindeman, Mark Clemons, et al.
Clinical Breast Cancer|September 26, 2019
Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic InformationSusan J Robertson, Greg R Pond, John Hilton, et al.
Breast Cancer Research and Treatment|June 25, 2009
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patientsOrit Freedman, Eitan Amir, George Dranitsaris, et al.
The Oncologist|August 5, 2010
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortiumSara K Taylor, Stephen Chia, Susan Dent, et al.
Pageof 27